EMA's human medicines committee issued positive recommendations for multiple drugs, including Merck's Keytruda and InflaRx's ...
Eyenovia halted Phase 3 trial of atropine-based myopia treatment after data showed it wouldn't meet primary endpoint. CEO ...
Boston Pharmaceuticals succeeded on the two key endpoints for its Phase 2 MASH study, putting the company in contention with ...
ALX Oncology has found a new chief medical officer, tapping Alan Sandler for the role. Sandler comes to ALX from Mirati, ...
Adaptimmune Therapeutics announces 33% workforce reduction and restructuring to save $300 million through 2028. Company halts ...
Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...
Eli Lilly is now the second drugmaker to propose a rebate model for 340B drug price discounts — and the second to ...
Vitalli Bio ends Daewoong deal, Alector receives $50M Hercules Capital loan, Bavarian Nordic gets $340M vaccine orders, Nuvectis Pharma reports disappointing trial data, Flashpoint partners with Saudi ...
The European Medicines Agency has flipped its stance on Eisai and Biogen’s Alzheimer’s treatment Leqembi, recommending ...
Merz Therapeutics landed in hot water last month when the FDA said a social media promotion for its Botox rival Xeomin was ...
More cuts are hitting Gilead’s cell therapy wing, including the closure of a Philadelphia office. A small number of ...
New Zealand approved Tune Therapeutics' TUNE-401, an epigenetic editing therapy for chronic hepatitis B, for human trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback